Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

Completed

Conditions studied: Glaucoma

In brief

The purpose of this study is to evaluate the clinical outcomes of the Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) after 1 day, 1 week,1 month, 3 months, 6 months and one year of follow-up, with the intent to evaluate the efficacy of using MP-TSCPC to treat glaucoma patients.

Key facts

Study ID

NCT05654493

Run by

Mayo Clinic

People needed

65

Starts

2022-04-18

Expected to finish

2023-06-30

Last updated by the study team

2026-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnose of glaucoma
• Indication to be submitted to the procedure

You may not qualify if…

• Significant thinning of the sclera
• Current eye infection or inflammation
• Intraocular surgery performed less than 2 months prior to the enrollment in the study

Where it is running

• Mayo Clinic Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.